Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
April 01 2022 - 8:30AM
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that single ascending dose and multiple ascending dose data from
the Phase 1 study evaluating LP352 in healthy volunteers will be
presented at the American Academy of Neurology (AAN) Annual Meeting
being held in person April 2–7, 2022, in Seattle, WA, and virtually
April 24–26, 2022.
"At AAN, we are presenting data highlighting
favorable safety, tolerability, pharmacokinetics and
pharmacodynamics that were observed in our Phase 1 trial in healthy
volunteers. Importantly, we saw adverse events consistent with
expected effects of a serotonergic drug. 5-HT2c receptor engagement
was demonstrated by dose- and exposure-dependent increase of
prolactin," stated Dr. Randall Kaye, Chief Medical Officer. "These
data helped to inform our protocol design, including dosing, for
the Phase 1b/2a PACIFIC Study, our first in-patient study in which
we are evaluating LP352 in participants with a range of
developmental and epileptic encephalopathies. We look forward to
sharing more on the potential of LP352 for the treatment of severe
and refractory epilepsies as we advance the program."
Presentation Details:
Title: Single Ascending Dose
Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of
LP352 in Healthy Subjects (abstract #1750)Session:
P14: Epilepsy/Clinical Neurophysiology (EEG): ASM Clinical Trials 3
Date/Time: Wednesday, April 6 from 11:45 AM -
12:45 PM PT
Title: A Randomized,
Double-Blind, Placebo-Controlled, Multiple Ascending Dose
Pharmacokinetics (PK), Pharmacodynamics (PD), and Tolerability of
LP352 in Healthy Subjects (abstract #1771)Session:
P14: Epilepsy/Clinical Neurophysiology (EEG): ASM Clinical Trials 3
Date/Time: Wednesday, April 6 from 11:45 AM -
12:45 PM PT
About LP352LP352 is a highly
selective, oral, centrally acting, next-generation 5-HT2c receptor
superagonist in development for the potential treatment of seizures
associated with developmental and epileptic encephalopathies (DEEs)
such as Dravet syndrome, Lennox-Gastaut syndrome (LGS), tuberous
sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), and other
epileptic disorders. LP352 is designed to modulate GABA inhibition
and, as a result, suppress the central hyperexcitability that is
characteristic of seizures. LP352 has demonstrated negligible
observed impact on 5-HT2b and 5-HT2a receptor subtypes in the
Company’s preclinical studies to date. 5-HT2b and 5-HT2a receptor
agonism have been associated with significant adverse effects.
LP352 has novel chemistry and attributes, and was designed to be
more specific and selective for the 5-HT2c receptor subtype, giving
it the potential to reduce seizures in DEE patients while
overcoming the known or perceived safety limitations of available
drugs in the 5-HT2 class. LP352 is currently being evaluated in the
Phase 1b/2a PACIFIC Study in approximately 50 participants with a
range of DEEs.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of
GPCR research. Longboard is evaluating LP352, an oral, centrally
acting 5-hydroxytryptamine 2c (5-HT2c) receptor superagonist, with
negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes,
in development for the potential treatment of seizures associated
with a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
in development for the potential treatment of multiple neurological
diseases, and LP143, a centrally acting, full cannabinoid type 2
receptor (CB2) agonist, in development for the potential treatment
of central nervous system (CNS) diseases and disorders.
Forward-Looking
StatementsCertain statements in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Such forward-looking statements include statements
about Longboard’s participation in the upcoming meeting, clinical
and preclinical programs, ability to develop medicines, and focus.
For such statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
Corporate Contact:
Megan E. Knight
Head of Investor Relations
mknight@longboardpharma.com
IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024